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Abstract
Background: To assess the measurement properties of the Benign Prostatic Hyperplasia Impact Index (BII) for use
in men with Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH) treated with
tadalafil.
Methods: Data from a dose-titration (Study 1) and a dose-finding placebo-controlled (Study 2) tadalafil studies of
men 45 years of age or older with moderate to severe LUTS (N = 281; N = 1053) were included in this post-hoc
analysis. Measures included the BII, International Prostate Symptom Score (IPSS), IPSS Quality of Life Index (IPSS-
QoL), LUTS Global Assessment Question, uroflowmetry measure peak flow rate (Qmax) and postvoid residual volume
(PVR). Spearman rank and Pearson correlation coefficients were computed between the BII score and the other
measures at each visit. Wilcoxin two-sample tests, t-tests and general linear modeling compared BII scores of
subjects with global ratings of improvement versus no improvement, and subjects taking tadalafil versus placebo.
Effect size, standardized response mean and Guyatt’s responsiveness statistic were calculated for BII and IPSS
change scores.
Results: There were high correlations between BII and IPSS & IPSS-QoL and low correlations between BII and Qmax &
PVR at each visit. There were significant differences in BII at the End-of-Study Visit between subjects reporting
improvement versus subjects reporting no improvement (Studies 1 and 2, P < .0001) and subjects taking tadalafil
versus subjects taking placebo (Study 1, P = .0045; Study 2, P = .0064). The BII and IPSS were both responsive to
change.
Conclusions: Results show that the BII is reliable, shows responsiveness to change in patients with BPH-LUTS, and
demonstrates construct validity.
Background
Benign prostatic hyperplasia (BPH) is commonly found
in aging men and is characterized by the presence of
stromal and epithelial cell hyperplasia beginning in the
periurethral zone of the prostate [1-4]. BPH becomes a
clinical entity when associated with lower urinary tract
symptoms (LUTS); the most common manifestation of
BPH [1,2]. Patients with BPH-LUTS experience a signifi-
cant deterioration in quality of life because of their con-
dition, reporting changes in sleep patterns, anxiety and
embarrassment, altered mobility, changes in leisure,
daily-living and sexual activities and in satisfaction with
sexual relationships [3]. In some men, the progressive
enlargement of the prostate may lead to worsening
symptoms, acute urinary retention, and consequently,
surgical intervention [3].
The primary goal for treating men with BPH-LUTS is
usually to relieve symptoms and the bother they cause
[5]. In patients with moderate to severe bothersome
symptoms treatment options include medical therapies,
such as alpha (a) blockers, or in men with an enlarged
prostate, 5-a-reductase inhibitors as monotherapy or in
combination [4-6].
The most widely employed and validated scoring system
for quantifying and monitoring of BPH-LUTS is the 7-
item American Urological Association (AUA) Symptom
Index developed by the Measurement Committee of the
AUA [7]. This instrument measures the severity of voiding
and storage symptoms (see Appendix 1) and is the first 7
items of the International Prostate Symptom Score,
referred to in this article as the IPSS (see Appendix 1).
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Index (BII) to assess the impact of BPH symptoms on
patient health and functioning [8]. The BII is a self-
administered questionnaire with 4 questions about urin-
ary problems during the past month regarding physical
discomfort, worry about health, how bothersome symp-
toms are, and whether the symptoms are interfering
with doing usual activities (see Appendix 2).
The BII has successfully demonstrated responsiveness
to change in patients with BPH-LUTS who were being
treated with terazosin versus placebo [9] and dutasteride
versus placebo [10,11]. The BII has demonstrated the
ability to detect significant differences between men
with symptomatic benign prostatic obstruction (with
and without indwelling catheter) before and after inter-
vention [12]. Changes in BII scores were greater for
BPH-LUTS patients who reported overall global
improvement compared to those reporting only moder-
ate, slight, or no improvement [13].
New classes of drugs are currently under investigation
for the treatment of men with BPH-LUTS, one being
tadalafil, a long-acting phosphodiesterase type 5 (PDE-5)
inhibitor used for men with erectile dysfunction (ED).
Several reports have shown possible links between BPH-
LUTS and ED in epidemiologic, pathophysiologic, and
treatment aspects [14].
The initial validation of the BII was carried out 15
years ago by Barry et al [8]. Since that time, the nature
of study populations, study designs and treatment
options have changed. The BII is an evaluative index
useful in measuring the magnitude of change in the
impact of BPH-LUTS within a person over time. Its use-
fulness in BPH treatment is dependent upon it being
reliable, responsive to change, and valid. Therefore, it is
important to evaluate the construct validity of the BII
for patients receiving newer medical treatment such as
tadalafil.
Methods
The BII was administered in 2 clinical studies. Study 1
was a proof-of-concept, randomized, double-blind, pla-
cebo-controlled, parallel-design 12-week dose-titration
study. Study 2 was a randomized, 5-group, double-blind,
placebo-controlled, parallel-design dose-finding 12-week
study. Men who were at least 45 years of age, with mod-
erate to severe LUTS due to BPH and evidence of blad-
der obstruction, were eligible to participate in both
studies. Details of the study designs and populations
have previously been published [15,16]. The two studies
were in compliance with the Helsinki Declaration.
In each study, subjects were screened at Visit 1. If
necessary, they started a 4-week washout of BPH treat-
ments; otherwise subjects returned in approximately 1
week. At Visit 2, subjects were required to have an IPSS
≥ 13 and an uroflowmetry measure of peak flow rate
(Qmax) ≥ 4t o≤ 15 mL/second on a voided volume of
125 mL to continue in the study. Each study included a
4 week single-blind, placebo run-in period to assess
treatment compliance and establish baseline levels at its
conclusion. At Visit 3 (Week 0), baseline measures were
obtained and subjects were randomly assigned to
treatment.
Treatment in Study 1 was either tadalafil 5 mg for
6 weeks followed by tadalafil 20 mg for 6 weeks, or pla-
cebo for 12 weeks. Subjects returned on Visit 4 (Week 6),
and Visit 5 (Week 12), which was the End-of-Study Visit.
Treatment in Study 2 was tadalafil 2.5, 5, 10, 20 mg,
or placebo in a 1:1:1:1:1 ratio. The treatment period
lasted 12 weeks. Subjects returned on Visit 4 (Week 4),
Visit 5 (Week 8), and Visit 6 (Week 12), which was the
End-of-Study Visit.
For both studies, subjects completed the BII at every
v i s i ts t a r t i n ga tV i s i t2 .A l lq u e s t i o n sa s k e dw e r ea b o u t
problems over the past month. The first 3 questions of
the BII were scored 0 to 3, while the fourth was scored
0 to 4. The sum of the questions produced a BII score
that ranged from 0 to 13, with a higher score indicating
a worse health impact of BPH symptoms (Appendix 2).
Other questionnaires assessing BPH-LUTS included
the IPSS, IPSS-Quality of Life (QoL) and the Global
Assessment Questionnaire (GAQ). The IPSS is a vali-
dated 7-item urinary symptom severity scale about
symptoms occurring over the past month. Scores ranged
from 0 to 35 with a higher score indicating more severe
symptoms. The IPSS-QoL is a single question: “If you
were to spend the rest of your life with your urinary
condition just the way it is now, how would you feel
about that?” with scores of 0 (delighted), 1 (pleased), 2
(mostly satisfied), 3 (mixed about equally satisfied and
dissatisfied), 5 (mostly dissatisfied), and 6 (terrible). The
GAQ is a global measure of improvement and was
asked at the End-of-Study Visit: “Has the treatment you
have been taking during this study improved your urin-
ary symptoms?” with patients responding yes or no.
Objective measures included measuring peak urine
flow rate (Qmax), and postvoid residual volume (PVR),
which assesses lower urinary tract function. Both mea-
sures are often included in clinical trials in men with
BPH-LUTS; however, both are considered optional by
the AUA following the initial evaluation of patients for
BPH-LUTS [4].
Statistical Analyses
Construct validity is the ability of an instrument to mea-
sure the degree to which an individual possesses a
hypothetical trait or quality. Construct validity may be
measured by an instrument’ss t r o n gr e l a t i o n s h i pw i t h
other instruments that are intended to measure the
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ship with other instruments that measure different con-
cepts (discriminant validity).
The data from each study was analyzed separately. For
all analyses, unless explicitly mentioned, subjects were
included regardless of what type of treatment they
received.
Internal consistency reliability was assessed using
Cronbach’s alpha statistic [17]. Cronbach’s alpha > .70 is
considered acceptable, > .80 good and > .90 excellent
[18]. Spearman rank correlation coefficients and Pearson
correlation coefficients were computed between the BII,
IPSS, IPSS-QoL, Qmax and PVR at each visit. Correla-
tions demonstrating validity typically range from .30 to
.80 [19]. Expectations were that BPH-LUTS severity (i.e.
IPPS) and related bothersomeness (i.e. IPSS-QoL),
which measure concepts similar to BII, would be more
highly correlated with BII than the objective measures
(i.e., Qmax and PVR), which measure different concepts.
To demonstrate known-groups validity and test for dif-
ferences between groups expected to be different after
treatment, Wilcoxin two-sample tests and t-tests were
used to compare BII scores at the End-of-Study Visit
between subjects with global ratings of improvement
versus no improvement on the GAQ, and between sub-
jects taking tadalafil versus subjects taking placebo. SAS
9.1 for Windows General Linear Models (GLM) Proce-
dure was used for comparisons similar to the t-tests,
with the addition of initial or pre-treatment BII score as
a covariate. The percentage of men who received tadala-
fil and improved, and the percentage of men who
received placebo and improved were computed for each
study. Effect size, standardized response mean, and
Guyatt’s responsiveness statistic were calculated using
BII and IPSS change scores (End-of-Study Visit score
minus Visit 2 score) to compare the responsiveness, or
the ability to detect change, of the 2 measures [20].
Values of .20, .50, and .80 or greater indicate small,
moderate, and large responsiveness, respectively [21].
Results
Study 1 Subjects
A total of 281 men met the entry criteria and completed
the BII at Visit 2. The mean age among those randomized
at Visit 3 was 61.5 years (SD = 8.8, range from 45 to 82).
Participants were enrolled from 21 study sites across the
United States. A total of 55.2% had BPH-LUTS for more
than 3 years. After the placebo run-in period, 278 com-
pleted the BII at randomization Visit 3. At Visits 4 and 5,
270 and 259 men, respectively, completed the BII.
Study 2 Subjects
A total of 1053 men met the criteria and completed the
BII at Visit 2. The mean age among those randomized
at Visit 3 was 62.1 years old (SD = 7.9, range from 45 to
92). Participants for Study 2 were enrolled from 92
study sites across 10 countries. A total of 51.4% had
BPH-LUTS for more than 3 years. After the placebo
run-in period there were 1052 who completed the BII at
Visit 3 at randomization. Visits 4 through 6 included
1016, 937, and 896 men, respectively, who completed
the BII.
Reliability
Cronbach’s alpha for BII was computed at each visit and
ranged from .78 to .85 for Study 1 and .81 to .86 for Study
2. Test-retest reliability was not evaluated due to potential
deterioration of the patient condition during the washout
period. However, the first and second time BII was admi-
nistered occurred before and after the 4-week placebo
run-in for all subjects. Spearman rank correlation coeffi-
cients between BII Visit 2 and BII Visit 3 were rs = .63 for
Study 1 and rs = .64 for Study 2; Pearson correlation coef-
ficients were r=. 6 5a n dr= .65 respectively.
Validity
For both studies, the initial BII, IPSS, IPSS-QoL, Qmax
and PVR assessment used in the analyses were at Visit
2. Table 1 displays the Spearman rank correlation coeffi-
cients between the BPH measures at each visit by study.
The BII and IPSS-QoL are all subjective measures of
symptoms and/or impact of BPH-LUTS. The IPSS is a
urinary symptom severity scale that measures the sever-
ity of symptoms of BPH_LUTS. At each visit of Studies
1 and 2, the BII correlated well with IPSS (rs =. 3 9t o
.67) and IPSS-QoL (rs = .56 to .70). The other 2 vari-
ables were objective measures of BPH-LUTS (Qmax and
PVR). At each visit of Studies 1 and 2, BII had very low
correlations with Qmax (rs = -.13 to .01) and PVR (rs=
.00 to .14). Pearson correlations were very similar.
To demonstrate known-groups validity for BII in each
study, subjects who indicated on the GAQ that treat-
ment had improved their symptoms at the End-of-Study
Visit were compared to subjects who indicated no
improvement. Table 2 displays the 25
th percentiles,
medians, 75
th percentiles, means and standard deviations
for improved and not improved subjects. Baseline scores
are shown also. There was a significant difference
between improved and not improved subjects for both
studies (Study 1: Wilcoxin two-sample test z = 5.03, P <
.0001, t-test (df = 256) = 5.16, P < .0001; Study 2: Wil-
coxin two-sample test z = 10.24, P < .0001, t-test (df =
469) = 10.64, P < .0001). The GLM results were very
similar to the t-tests (Study 1 least-squares means:
Improved = 2.91, Not improved = 4.97; Study 2 least-
squares means: Improved = 2.90, Not improved = 5.04).
To demonstrate differences between groups that are
expected to be different after treatment, BII scores at the
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pared with subjects taking placebo in each study. Table 3
displays the 25
th percentiles, medians, 75
th percentiles,
means and standard deviations for tadalafil and placebo sub-
jects. Baseline scores are shown also. There were significant
differences between tadalafil and placebo subjects for both
studies (Study 1: Wilcoxin two-sample test z =2 . 8 4 ,P=
.0045, t-test (df = 254) = 2.65, P = .0085; Study 2: Wilcoxin
two-sample test z = 2.73, P=.0064, t-test (df = 892) = 2.68,
P = .0076). Since tadalafil treatment started at Visit 3, GLM
was used to compare the 2 groups while controlling for BII
at Visit 3. Results were very similar to the t-tests (Study 1
least-squares means: tadalafil = 3.61, placebo = 4.39; Study 2
least-squares means: tadalafil = 3.46, placebo = 4.03).
Table 1 Spearman Rank Correlation coefficients among BPH Measures at each visit
Study 1 Study 2
Visit 2 BII IPSS IPSS-QoL Qmax Visit 2 BII IPSS IPSS-QoL Qmax
IPSS 0.39 IPSS 0.51
IPSS-QoL 0.63 0.42 IPSS-QoL 0.56 0.55
Qmax 0.01 -0.12 0.05 Qmax -0.01 -0.10 -0.02
PVR 0.00 0.11 0.06 -0.12 PVR 0.03 0.16 0.06 -0.21
Visit 3 BII IPSS IPSS-QoL Qmax Visit 3 BII IPSS IPSS-QoL Qmax
IPSS 0.46 IPSS 0.53
IPSS-QoL 0.61 0.53 IPSS-QoL 0.56 0.56
Qmax -0.01 -0.16 -0.01 Qmax -0.05 -0.16 -0.10
PVR 0.03 0.09 0.02 -0.19 PVR 0.05 0.13 0.11 -0.16
Visit 4 BII IPSS IPSS-QoL Qmax Visit 4 BII IPSS IPSS-QoL Qmax
IPSS 0.57 IPSS 0.60
IPSS-QoL 0.65 0.59 IPSS-QoL 0.62 0.66
Qmax -0.08 -0.24 -0.13 Qmax -0.12 -0.24 -0.17
PVR 0.01 0.05 0.04 -0.10 PVR 0.12 0.18 0.12 -0.18
Visit 5 BII IPSS IPSS-QoL Qmax Visit 5 BII IPSS IPSS-QoL Qmax
IPSS 0.64 IPSS 0.66
IPSS-QoL 0.66 0.64 IPSS-QoL 0.67 0.70
Qmax -0.08 -0.17 -0.14 Qmax -0.09 -0.28 -0.18
PVR 0.00 0.08 0.01 -0.02 PVR 0.11 0.17 0.14 -0.23
Visit 6 BII IPSS IPSS-QoL Qmax
IPSS 0.67
IPSS-QoL 0.70 0.73
Qmax -0.13 -0.25 -0.23
PVR 0.14 0.21 0.20 -0.22
Table 2 BII Scores for subjects with GAQ Global Ratings of “Improved” versus “Not improved” at End-of-study Visit
Study 1
25th Percentile Median 75th Percentile Mean SD
Improved Baseline 5.00 7.00 8.00 6.50 2.81
(n = 121) End-of-Study 1.00 3.00 5.00 3.08 2.64
Not improved Baseline 4.00 6.00 8.00 5.91 2.80
(n = 137) End-of-Study 3.00 5.00 6.00 4.81 2.72
Study 2
25
th Percentile Median 75th Percentile Mean SD
Improved Baseline 4.00 6.00 8.00 5.74 2.98
(n = 608) End-of-Study 1.00 2.00 4.00 2.87 2.55
Not improved Baseline 4.00 6.00 8.00 5.94 3.00
(n = 283) End-of-Study 3.00 5.00 7.00 5.11 3.08
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Responsiveness statistics were calculated for the BII and
the IPSS. The effect size, standardized response mean,
and Guyatt’s responsiveness statistic for BII were: .78,
.79, and 1.02 (respectively) for Study 1 and .74, .75, and
.82 (respectively) for Study 2. The corresponding
response statistics for the IPSS were: 1.35, 1.15, and 1.31
for Study 1 and 1.39, 1.15, and 1.38 for Study 2.
Although the IPSS values were greater than the BII,
both measures appeared to be responsive to change.
Discussion
T h eB I Ii saB P H - s p e c i f i cm e a s u r et h a ta s s e s s e st h e
impact of BPH symptoms on patient health and func-
tioning. Cronbach’s alpha for BII ranged from .78 to .85
for Study 1 and .81 to .86 for Study 2, indicating high
internal consistency. BII correlated well at each visit
with IPSS and IPSS-QoL, measures of BPH symptoms
and overall bother of BPH, respectively, which measure
concepts similar to BII. These correlations support BII
has convergent validity. In contrast, objective measures
of BPH such as Qmax and PVR, which measure different
concepts than BII, had very low correlations with BII at
each visit. These low correlations offer evidence to sup-
port discriminant validity for the BII. It has been recog-
nized for some time in the urological community that
urodynamic measures such as Qmax and PVR are not
associated with the symptoms of BPH-LUTS itself [22].
Construct validity also may be established by comparing
groups that are known to differ on the concept of interest
(known-groups validity) or comparing groups that are
expected to differ after experimental manipulation. BII dif-
ferentiated between subjects who indicated treatment had
improved their urinary symptoms compared to subjects
with no improvement, lending support for known-groups
validity. BII also differentiated between subjects taking
tadalafil compared to subjects taking placebo, establishing
that BII can distinguish groups that are expected to differ
after therapeutic intervention. More subjects receiving
tadalafil improved than subjects receiving placebo in both
studies. The purpose of the analyses in this manuscript
was not to identify who improved on placebo or different
doses of tadalafil (2.5 mg, 5 mg, 10 mg or 20 mg), but to
conduct a construct validityo faB P Hb o t h e rs c o r et o o l .
The 2 studies are very different with different dosing and
duration of a specific dosing, which makes the studies sui-
table for validity assessment, but very heterogeneous and
therefore unsuitable for comparison.
Our results support 2 validation studies that found
strong correlations between BII and IPSS [7,8] and
other studies that found strong correlations between BII
and IPSS-QoL [11,23,24]. Our findings that BII can dif-
ferentiate known-groups is consistent with BPH treat-
ment studies that showed BII differentiated between
levels of global patient improvement [13], between drug
therapy and placebo [10], and between treatment
options [11].
The responsiveness statistics calculated for BII indi-
cate that BII is responsive to change. BII should be able
to detect when clinically relevant change occurs in a
clinical trial or a treatment setting.
The IPSS was the primary efficacy measure in the 2
clinical trials. Given that the BII correlates well with the
IPSS, one might question what additional benefit it
offers. The correlations between BII and IPSS in Study 1
at Visit 5 (rs = .64, r = .67) and in Study 2 at Visit 6 (rs
= .67, r = .68) were strong but they indicated that the
IPSS accounted for only 45% and 46% of BII variance,
respectively. The BII is a subjective measure and IPSS is
a urinary symptom severity measure of BPH-specific
health status. While the IPSS addresses specific symp-
toms that the patient may experience, the BII addresses
how BPH symptoms impact the patient. The IPSS-QoL
consists of a general question about the impact of BPH
Table 3 BII scores at End-of-Study visit for subjects taking Tadalafil or placebo
Study 1
25
th Percentile Median 75th Percentile Mean SD
Tadalafil Baseline 3.00 5.00 7.00 4.98 2.99
(n = 125) End-of-Study 2.00 3.00 5.00 3.54 2.78
Placebo Baseline 3.00 5.00 7.00 5.21 2.73
(n = 131) End-of-Study 3.00 4.00 6.00 4.46 2.78
Study 2
25
th Percentile Median 75th Percentile Mean SD
Tadalafil Baseline 3.00 5.00 7.00 4.73 2.88
(n = 707) End-of-Study 1.00 3.00 5.00 3.45 2.88
Placebo Baseline 3.00 4.00 7.00 4.86 2.95
(n = 187) End-of-Study 2.00 4.00 6.00 4.09 2.97
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tions with BII in Study 1 at Visit 5 (r s =. 6 6 ,r =. 6 9 )
a n di nS t u d y2a tV i s i t6( r s =. 7 0 ,r =. 7 1 )b u tt h e
IPSS-QoL accounted for only 48% and 50%, respectively,
of BII variance. The BII measures more specifically the
impact of BPH symptoms, including physical discomfort,
worry about health, how bothersome symptoms are, and
whether the symptoms are interfering with doing usual
activities.
When the primary goal for treating patients with clini-
cal manifestations of BPH is to relieve bothersome
symptoms, the BII could be used to measure symptom
impact on patients. Future research will be necessary to
determine if the BII is useful in predicting patient out-
comes. This study demonstrates that BII is useful for
clinical trials that evaluate drug therapy designed to
affect the impact of BPH symptoms on patient health
and functioning.
Conclusions
The results demonstrate that BII is reliable, shows
responsiveness, and has construct validity. The BII is a
valid instrument to assess the impact of BPH symptoms
on health and functioning in clinical trial settings.
Appendices
Additional material
Additional file 1: International Prostate Symptom Score (IPSS).
Additional file 2: BPH Impact Index (BII).
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